PMDA drug package insert
リナグリプチン錠5mg「ZE」
PMDA Prescription drug · 全星薬品工業株式会社 · package insert Aug 18, 2026
Key facts
| Brand names | リナグリプチン錠5mg「ZE」 |
|---|---|
| Nonproprietary names | リナグリプチン |
| Companies | 製造販売元／全星薬品工業株式会社, 発売元／全星薬品株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 胆汁排泄型選択的DPP-4阻害剤 －2型糖尿病治療剤－ |
| Therapeutic category codes | 873969 |
| YJ codes | 39690B3F1074 |
| Approval numbers | 30800AMX00247000 |
| Package insert edition | 第1版 |
| Package insert date | Aug 18, 2026 |
| PMDA document key | 380087_39690B3F1074_1 |
| PMDA company code | 380087 |
At a glance
- 1–9 Package insert revisions
- None Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: